|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-5
|
|
pubmed:abstractText |
The cytokine tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown promising anticancer activity in early clinical settings by selectively inducing apoptosis in different tumour types. However, some tumour entities such as hepatocellular carcinoma (HCC) display an inherent resistance to TRAIL. A huge effort has been made to unravel strategies for a clinically applicable sensitisation of resistant cancer cells to TRAIL. Reversible epigenetic alterations such as DNA methylation play a major role in development, maintenance and resistance phenomena of tumour cells. Currently, several clinical trials are exploiting the potential of epigenetic drugs, such as 5-azacytidine (5-aza-CR) or 5-aza-2'-deoxycytidine (5-aza-dC) to break primary or secondary resistance phenomena of cancer cells. Therefore, 5-aza-CR and 5-aza-dC were investigated in the context of TRAIL resistance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Azacitidine,
http://linkedlifedata.com/resource/pubmed/chemical/CASP8 and FADD-Like Apoptosis...,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/TNF-Related Apoptosis-Inducing...,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF10 protein, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1468-3288
|
|
pubmed:author |
pubmed-author:BergerAlexanderA,
pubmed-author:BitzerMichaelM,
pubmed-author:FuldaSimoneS,
pubmed-author:GregorMichaelM,
pubmed-author:HäckerSabineS,
pubmed-author:KönigsrainerAlfredA,
pubmed-author:LauerUlrich MUM,
pubmed-author:PeterChristophC,
pubmed-author:VenturelliSaschaS,
pubmed-author:WeilandTimoT,
pubmed-author:WeissThomas STS,
pubmed-author:WesselborgSebastianS,
pubmed-author:ZimmermannMartinaM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
156-65
|
|
pubmed:meshHeading |
pubmed-meshheading:21106551-Antimetabolites, Antineoplastic,
pubmed-meshheading:21106551-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21106551-Azacitidine,
pubmed-meshheading:21106551-CASP8 and FADD-Like Apoptosis Regulating Protein,
pubmed-meshheading:21106551-Carcinoma, Hepatocellular,
pubmed-meshheading:21106551-Caspases,
pubmed-meshheading:21106551-Cell Proliferation,
pubmed-meshheading:21106551-DNA, Neoplasm,
pubmed-meshheading:21106551-DNA Methylation,
pubmed-meshheading:21106551-Down-Regulation,
pubmed-meshheading:21106551-Drug Evaluation, Preclinical,
pubmed-meshheading:21106551-Drug Resistance, Neoplasm,
pubmed-meshheading:21106551-Enzyme Activation,
pubmed-meshheading:21106551-Epigenesis, Genetic,
pubmed-meshheading:21106551-Humans,
pubmed-meshheading:21106551-Liver Neoplasms,
pubmed-meshheading:21106551-Neoplasm Proteins,
pubmed-meshheading:21106551-TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:21106551-Tumor Cells, Cultured
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation.
|
|
pubmed:affiliation |
Department of Internal Medicine I, Medical University Hospital, Otfried-Mueller-Str. 10, D-72076 Tuebingen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
